Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes
| العنوان: | Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes |
|---|---|
| المؤلفون: | L, Kappos, C H, Polman, M S, Freedman, G, Edan, H P, Hartung, D H, Miller, X, Montalban, F, Barkhof, L, Bauer, P, Jakobs, C, Pohl, R, Sandbrink |
| المصدر: | Neurology. 67:1242-1249 |
| بيانات النشر: | Ovid Technologies (Wolters Kluwer Health), 2006. |
| سنة النشر: | 2006 |
| مصطلحات موضوعية: | Adult, Male, Canada, Multiple Sclerosis, Time Factors, Interferon-beta, Syndrome, Placebo Effect, Risk Assessment, Disease-Free Survival, Europe, Treatment Outcome, Double-Blind Method, Risk Factors, Prevalence, Humans, Female, Neurology (clinical), Israel, Interferon beta-1b |
| الوصف: | To assess efficacy, safety, and tolerability of every-other-day interferon beta-1b treatment in patients with a first clinical event suggestive of multiple sclerosis (MS) (clinically isolated syndrome).We conducted a multicenter, randomized, double-blind, placebo-controlled trial. Patients with a first clinical demyelinating event and at least two clinically silent brain MRI lesions were randomized to interferon beta-1b (IFNB-1b) 250 mug subcutaneously (SC) every other day (EOD) (n = 292) or placebo (n = 176), until clinically definite MS (CDMS) was diagnosed or they had been followed for 24 months.After 2 years, 45% of placebo patients had converted to CDMS (Kaplan-Meier estimate; primary outcome measure) and 85% fulfilled the McDonald criteria (co-primary outcome measure). Overall interferon beta-1b delayed the time to diagnosis of CDMS (p0.0001) and McDonald MS (p0.00001). Hazard ratios (95% CI) were 0.50 (0.36 to 0.70) for CDMS and 0.54 (0.43 to 0.67) for McDonald MS favoring treatment with IFNB-1b. Treatment was well tolerated, as indicated by the low rate of patients dropping out of the study before CDMS was reached (6.6% overall, 7.2% in the IFNB-1b group).Interferon beta-1b 250 mug subcutaneously every other day delayed conversion to clinically definite multiple sclerosis, and should be considered as a therapeutic option in patients presenting with a first clinical event suggestive of multiple sclerosis. |
| تدمد: | 1526-632X 0028-3878 |
| DOI: | 10.1212/01.wnl.0000237641.33768.8d |
| URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::85d21069dd824591e4bb2b31d9bca326 https://doi.org/10.1212/01.wnl.0000237641.33768.8d |
| رقم الانضمام: | edsair.doi.dedup.....85d21069dd824591e4bb2b31d9bca326 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 1526632X 00283878 |
|---|---|
| DOI: | 10.1212/01.wnl.0000237641.33768.8d |